12:00 AM
 | 
Feb 18, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Nulojix belatacept regulatory update

Bristol-Myers and Germany's Statutory Health Insurance Funds Association (GKV-Spitzenverband) said they reached an agreement on the price for Nulojix belatacept to prevent organ rejection in adult kidney transplant...

Read the full 117 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >